- Net sales amounted to TSEK 291 (TSEK 219)
- Earnings before interest and taxes (EBIT) amounted to MSEK -7,9 (MSEK -7,8)
-
Earnings per share after dilution at
SEK -0,10 (SEK 0,09 ) - Cash flow from operating activities amounted to TSEK -5 779 (TSEK -4 887)
- Liquid assets at the end of the period MSEK 20,5 ( MSEK 11,5)
-
Equity ratio was 83 % (75 %)
- Net sales amounted to TSEK 1 198 (TSEK 653)
- Earnings before interest and taxes (EBIT) amounted to MSEK -24,3 (MSEK 11,0)
-
Earnings per share after dilution at
SEK -0,3 (SEK- 0,14) - Cash flow from operating activities amounted to TSEK -23 569 (TSEK -8 353)
- Liquid assets at the end of the period MSEK 20,5 (MSEK 11,5)
-
Equity ratio was 83 % (75 %)
SUMMARY OF EVENTS DURING FIRST QUARTER
RLS Global's notified bodies perform quality audits (ISO 13485 and MDD) without remarksKarin Fischer hands in her resignationConvatec is taking over the agreements with Swedish customers-
ChloraSolv is now delivered to the
Convatec central warehouse on a regular basis -
ChloraSolv is reimbursed in
the Netherlands
SUMMARY OF EVENTS DURING SECOND QUARTER
- Annual General Meeting is held
May 19 -
RLS signs distribution contract for
Middle East - RLS introduces ChloraSolv for the animal segment in Scandinavia by signing distribution contract with Swevet
-
ChloraSolv is approved for leg ulcers in
Kuwait
SUMMARY OF EVENTS DURING THIRD QUARTER
- An article regarding ChloraSolv is published in
Journal of Wound Care RLS Global strengthens its solvency by transforming a loan to share capital
SUMMARY OF EVENTS DURING FOURTH QUARTER
Björn Larsson starts as CEO-
RLS carries out a new share issue (rights issue) and thereby raises
SEK 26.8 million in cash and cash equivalents after issue costs The Swedish Medicines Agency approves RLS' application for a clinical study regarding pressure ulcers-
RLS takes part in the conference Wounds
UK inHarrogate, England
SUMMARY OF EVENTS AFTER FOURTH QUARTER
- An extra General Meeting is held
February 9, 2023 Lars Johansson is elected as Chairman of the Board-
RLS visits
Arab Health , a global health conference in theMiddle East and performs on-site distributor meetings and training sessions
The Year-end Report Q4, 2022, is enclosed and is also available here.
Publication
This information was submitted for publication through the agency of the below contact person, at 08.30 CET on
TRADING PLACE AND CERTIFIED ADVISER:
FOR MORE INFORMATION, PLEASE CONTACT:
E-mail: bjorn.larsson@rlsglobal.se
Tel: +46 766 20 17 25
Eva Jagenheim, CFO,
E-mail: eva.jagenheim@rlsglobal.se
Tel: +46 730 23 13 57
ABOUT
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as wound care and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at rls.global
https://news.cision.com/rls-global-ab/r/rls-global-ab--publ--year-end-report--q4--2022,c3724394
https://mb.cision.com/Main/12052/3724394/1879441.pdf
https://mb.cision.com/Public/12052/3724394/99675db0eccecb98.pdf
(c) 2023 Cision. All rights reserved., source